ADVANCING NEUROLOGICAL DIAGNOSTICS
An exosome platform providing a noninvasive, inexpensive, and robust diagnostic tool.
OUR VISION
At NeuroDex, we envision a world where effective and preventative
treatments for Alzheimer's exist.
The pharmaceutical industry has struggled over the past two decades to make headway in the Alzheimer's disease space due to a lack of inexpensive, noninvasive diagnostic tools. We want to bring the power of exosomes to the neurological diagnostic space - our technology has the potential to enable early detection, patient stratification, and disease monitoring, which we believe will enable the first disease-modifying treatment for Alzheimer's.
Our proprietary neuron-derived exosome isolation technology can be applied across a number of neurological indications. With our technology, a simple blood draw could allow physicians and researchers to open a window into the brain.
THE
NEURODEX
ADVANTAGE
Our lead indication is Alzheimer's disease, a poorly understood disease affecting a third of the 65+ age population.
QUICK-TO-MARKET
Leveraging regulatory FDA framework for Lab- Developed-Tests creates a quick to-market-opportunity
PLATFORM TECHNOLOGY
Capturing neuron derived exosomes enables identification of diverse pathological aspects
SAMPLE FLEXIBILITY
Use of frozen samples enables utilization of retrospective biobanks
TARGETED
Our data demonstrates a robust and high precision platform
SYNERGISTIC
We offer an isolation platform that can be combined with different detection methodologies
TEAM EXPERTISE
We have industry and academic experience in public and private diagnostic companies
OUR TEAM
EREZ EITAN
CSO, Co-founder
Dr. Eitan was the first to study exosome...
ODED BIRAN
CEO, Co-founder
Oded is an experienced diagnostics execu...
CHRISTINA MENDONCA
Controller
Christina is a Certified Public Account...
PUBLICATIONS FROM OUR TEAM
2019
Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of Aging
L1CAM isolation in a large cohort of pre-symptomatic AD. [link]
2017
Plasma Extracellular Vesicles Enriched for Neuronal Origin: A Potential Window into Brain Pathologic Processes
L1CAM isolation description of the method. [link]
2017
In a randomized trial in prostate cancer patients, dietary protein restriction modifies markers of leptin and insulin signaling in plasma extracellular vesicles
L1CAM isolation to detect diet effect on insulin resistance. [link]
2017
Walking speed decline in older adults is associated with elevated pro-BDNF in plasma extracellular vesicles
L1CAM isolation for accelerated motor decline with age [link]
2016
Extracellular Vesicle-Associated Aβ Mediates Trans-Neuronal Bioenergetic and Ca2+-Handling Deficits in Alzheimer's Disease Models
L1CAM isolation from mice. [link]
2015
Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study
L1CAM isolation and measurement of AD pathogenic proteins in AD and FTD. [link]
CONTACT
US
Please contact us with inquiries and questions at